IHC - HepPar 1/HS A Test, Price, Normal Range | Sprint Diagnostics Hyderabad

No, fasting is not required for the HepPar 1/ HS A IHC test.

The test involves taking a tissue sample from the tumor, which is then processed in a lab. The tissue is treated with antibodies specific for HepPar 1 and HS A, and any binding is visualized with a colored stain under a microscope.

This test is typically ordered when there is suspicion of hepatocellular carcinoma, based on other test results, symptoms, or the individual's medical history.

The test can provide crucial information about the origin of a tumor. If the tumor cells test positive for HepPar 1 and HS A, it suggests that the tumor likely originated from hepatocytes and might be hepatocellular carcinoma.

In normal liver tissue, HepPar 1 and HS A would be present. However, in a tumor, their presence or absence can suggest the origin of the tumor. Each individual case is different, and the results should be interpreted in the context of other clinical information.

No specific precautions are needed before or after this test. However, as the test involves taking a tissue sample, any instructions regarding wound care should be followed post-procedure.

Technical factors such as the quality of the tissue sample or the processing of the sample can affect the test results. Also, not all hepatocellular carcinomas will express HepPar 1/ HS A, so a negative result does not definitively rule out hepatocellular carcinoma.

If the test results are abnormal, it would be best to consult with the doctor who ordered the test, who could be a hepatologist or oncologist.

Non-modifiable factors could include the type and stage of the tumor. Modifiable factors are more related to technical aspects of the test, such as sample collection and processing.

The frequency of this test is not routine and is dependent on the need for diagnosis or monitoring of hepatocellular carcinoma or similar liver diseases. Your doctor will guide you based on your specific case and disease progression.

Yes, not all hepatocellular carcinomas express HepPar 1/ HS A. The levels can also be influenced by the stage of the tumor and can vary among different patients.

This test is primarily used for diagnosis and differentiation rather than monitoring. Other tests, such as imaging studies and blood tests, are usually used to monitor the progress of hepatocellular carcinoma.

Yes, this test is usually one part of a diagnostic workup that can include other tests like blood tests, imaging studies, and possibly other IHC tests, depending on the situation.

This depends on how the sample is collected. If the sample is obtained through a biopsy, there may be some discomfort or pain associated with the procedure. You will be given local anesthesia to minimize any discomfort.

The HepPar 1/ HS A IHC test plays an essential role in diagnosing and distinguishing hepatocellular carcinoma, helping to determine the most effective course of treatment. It is a specialized test that is ordered when there is a clinical suspicion of hepatocellular carcinoma or when a liver tumor's origin needs to be determined. Despite being a highly technical test, it is crucial in managing liver cancer effectively, providing a tailored approach to each patient's treatment. Always consult with your healthcare provider if you have any concerns or questions about this test.